On August 29th morning session, the medical sector showed strong activity with China's largest medical ETF (512170) climbing 1%, recording trading volume exceeding 490 million yuan by press time. The ETF maintains its leading position among similar funds with the latest assets under management reaching 27.535 billion yuan.
Among constituent stocks, CXO giant WUXI APPTEC led the sector with a 4% surge, while Sanbo Brain Hospital, New Industries Biomedical Engineering, and Wandong Medical Equipment followed with significant gains. Meinian Onehealth Healthcare and Winning Health Technology declined at the forefront.
The Medical ETF (512170) passively tracks the CSI Healthcare Index, whose top ten weighted stocks include Mindray Medical International, United Imaging Healthcare, Aier Eye Hospital Group, Tiger Medical, Imeik Technology Development, Lepu Medical Technology, New Industries Biomedical Engineering, Pharmaron Beijing, Yuyue Medical Equipment & Supply, and WUXI APPTEC.
On the news front, the 15th China International Conference on Medical Device Regulation was held in Suzhou on August 26th, where the National Medical Products Administration emphasized support for high-end medical device R&D innovation, having approved 52 innovative products this year.
Regarding weighted stock developments, United Imaging Healthcare's independently developed China's first photon-counting spectral CT received market approval, making it the world's first Chinese company to commercialize this technology.
Guoyuan Securities noted continued optimism for overseas expansion and centralized procurement clearance sectors in the second half of 2025. In overseas expansion, they favor companies with emerging market layouts due to significant development potential and trade friction avoidance. Under accelerated centralized procurement, the impact on insulin and orthopedics subsectors has cleared, with new growth expected ahead.
Additionally, pharmaceutical market concentration is accelerating, with M&A activities set to speed up. At the policy level, the government emphasizes strengthening original innovation and core technology development in biomedicine, promoting AI-enabled R&D and production, optimizing centralized procurement mechanisms, and advancing traditional Chinese medicine modernization. The National Financial Regulatory Administration plans to introduce policies deepening collaboration between health insurance and the health industry, providing sector support.
Zhongmail Securities highlighted that in medical devices, AI-enabled imaging/surgery directions receive attention, with domestic equipment benefiting from government procurement policy preferences. The medical consumables sector is expected to stabilize and recover as centralized procurement nears completion. The CXO industry's fundamentals are gradually recovering with notable marginal order improvements.
Data sourced from Shanghai and Shenzhen Stock Exchanges and public materials.
Risk Warning: The above products are issued and managed by fund management companies, and distribution agencies do not assume responsibility for product investment, redemption, and risk management. Investors should carefully read fund legal documents including Fund Contract, Prospectus, and Fund Product Summary to understand fund risk-return characteristics and select products matching their risk tolerance. Past fund performance does not predict future results, and fund investment requires caution! Sales institutions (including fund manager direct sales and other sales institutions) conduct risk assessments based on relevant laws and regulations. Investors should timely monitor appropriateness opinions issued by fund managers. Appropriateness opinions among sales institutions may not necessarily align, and fund product risk level assessments by sales institutions cannot be lower than those made by fund managers. Fund contract risk-return characteristics may differ from fund risk levels due to different consideration factors. Investors should understand fund risk-return situations and carefully select fund products based on their investment objectives, terms, experience, and risk tolerance while bearing risks independently. China Securities Regulatory Commission registration of the above funds does not indicate substantial judgment or guarantee of their investment value, market prospects, and returns. Fund investment requires caution.
MACD golden cross signal formed, these stocks show good upward momentum!